HSP90B2P and inclusion body myositis: Heat shock and the ALS models also served as initiating stresses to evaluate the HSP co-inducer, arimoclomol, which is in clinical trial for ALS and inclusion body myositis and exhibits a favorable safety profile (Lanka et al. 2009), as well as to determine if efficacy would be increased by combination with an HDAC inhibitor.